Under one in 10 people eligible to benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it publishes its inaugural advice on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per estimates, over two billion are projected to be obese by 2030 without intervention.
"Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with thorough and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key barriers to universal availability to the injections that can assist patients in reducing substantial weight, notes the agency.
Weight-Loss Drug Supply Crisis
Even in the current most favorable case, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, as stated by the health organization.
The guideline encourages governments and firms to increase availability, by strategies such as licensing agreements.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Jabs Function
These medications imitate a body's own hormone to slow digestion, curb appetite and boost satiety so users eat less.
Individuals commonly see weight reduction after several weeks of starting on the weekly injections.
Studies suggests patients may put most of the weight back on within a year of halting the medication, because their normal hunger come back.
To be carrying excess weight increases your risk for developing health problems, such as diabetes, heart disease, brain attack, and specific malignancies.
Excess weight concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
